Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

14,794 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Efficacy and Freedom: Patient Experiences with the Transition from Daily Oral to Long-Acting Injectable Antiretroviral Therapy to Treat HIV in the Context of Phase 3 Trials.
Mantsios A, Murray M, Karver TS, Davis W, Margolis D, Kumar P, Swindells S, Bredeek UF, García Del Toro M, Garcia Gasalla M, Rubio García R, Antela A, Hudson K, Griffith S, Kerrigan D. Mantsios A, et al. Among authors: kumar p. AIDS Behav. 2020 Dec;24(12):3473-3481. doi: 10.1007/s10461-020-02918-x. AIDS Behav. 2020. PMID: 32410051 Clinical Trial.
"I feel empowered": women's perspectives on and experiences with long-acting injectable antiretroviral therapy in the USA and Spain.
Mantsios A, Murray M, Karver TS, Davis W, Margolis D, Kumar P, Swindells S, Bredeek UF, Deltoro MG, García RR, Antela A, Garris C, Shaefer M, Gomis SC, Bernáldez MP, Kerrigan D. Mantsios A, et al. Among authors: kumar p. Cult Health Sex. 2021 Aug;23(8):1066-1078. doi: 10.1080/13691058.2020.1752397. Epub 2020 May 21. Cult Health Sex. 2021. PMID: 32436478
Multi-level considerations for optimal implementation of long-acting injectable antiretroviral therapy to treat people living with HIV: perspectives of health care providers participating in phase 3 trials.
Mantsios A, Murray M, Karver TS, Davis W, Galai N, Kumar P, Swindells S, Bredeek UF, García RR, Antela A, Gomis SC, Bernáldez MP, Czarnogorski M, Hudson K, Walters N, Kerrigan D. Mantsios A, et al. Among authors: kumar p. BMC Health Serv Res. 2021 Mar 20;21(1):255. doi: 10.1186/s12913-021-06214-9. BMC Health Serv Res. 2021. PMID: 33743684 Free PMC article. Clinical Trial.
Phase 3 Study of Ibalizumab for Multidrug-Resistant HIV-1.
Emu B, Fessel J, Schrader S, Kumar P, Richmond G, Win S, Weinheimer S, Marsolais C, Lewis S. Emu B, et al. Among authors: kumar p. N Engl J Med. 2018 Aug 16;379(7):645-654. doi: 10.1056/NEJMoa1711460. N Engl J Med. 2018. PMID: 30110589 Free article. Clinical Trial.
Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection.
Kozal M, Aberg J, Pialoux G, Cahn P, Thompson M, Molina JM, Grinsztejn B, Diaz R, Castagna A, Kumar P, Latiff G, DeJesus E, Gummel M, Gartland M, Pierce A, Ackerman P, Llamoso C, Lataillade M; BRIGHTE Trial Team. Kozal M, et al. Among authors: kumar p. N Engl J Med. 2020 Mar 26;382(13):1232-1243. doi: 10.1056/NEJMoa1902493. N Engl J Med. 2020. PMID: 32212519 Clinical Trial.
Safety, tolerability, and efficacy of raltegravir in a diverse cohort of HIV-infected patients: 48-week results from the REALMRK Study.
Squires KE, Bekker LG, Eron JJ, Cheng B, Rockstroh JK, Marquez F, Kumar P, Thompson M, Campo RE, Mounzer K, Strohmaier KM, Lu C, Rodgers A, Jackson BE, Wenning LA, Robertson M, Nguyen BY, Sklar P; REALMRK Investigators. Squires KE, et al. Among authors: kumar p. AIDS Res Hum Retroviruses. 2013 Jun;29(6):859-70. doi: 10.1089/AID.2012.0292. Epub 2013 Feb 26. AIDS Res Hum Retroviruses. 2013. PMID: 23351187 Free PMC article. Clinical Trial.
14,794 results
You have reached the last available page of results. Please see the User Guide for more information.